Skip to content

A Study of Ivermectin Lotion 0.5% w/w for the Treatment of Pediculus humanus capitis (head lice) Infestation

A Comparative, Two arm, Randomized, Double blind, Parallel Group, Vehicle Controlled Clinical Study to Evaluate Efficacy and Safety of Ivermectin Lotion 0.5% w/w for the Treatment of Pediculus humanus capitis (head lice) Infestation

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016125
Enrollment
219
Registered
2018-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Ivermectin Lotion 0.5% w/w: One tube of lotion is to be applied for 10 minutes to coat the hair and scalp. Rinse off with water. Use sterile hand gloves during application of the lotion

Sponsors

Ajanta Pharma Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects meeting all of the following criteria will be recruited for the trial: 1. Healthy males, non-pregnant females and children of age >=6 months to 2. Subjects must have an active head lice infestation of atleast three live lice and/or viable nits. (Viability of nits to be determined by using magnifying lens at a distance of less than 0.6 cm/6 mm from the scalp). 3. Following application and rinsing of the test article, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24 hour post treatment evaluation has been completed. 4. Subject agrees not to cut or chemically treat their hair while participating in the study. 5. Subject and/or parent/guardian agree that the subject will not use any other form of lice treatment during the duration of the study. 6. Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures. Caregivers who are willing to sign Informed Consent agreement for children of age =7 years who are willing to sign a childâ??s assent form.

Exclusion criteria

Exclusion criteria: Subjects will be excluded if ANY of the following conditions apply: 1. Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study. 2. Scalp condition that could make it difficult to evaluate the extent and severity of an infestation or that would present a problem in the evaluation of response to therapy (e.g. psoriatic scalp lesions, extensive seborrheic dermatitis). 3. Treatment for head lice (OTC, home remedy and/or prescription drugs) in the last 7 days. 4. Subject who used any hair dye, bleaches, hair straightening or permanent wave solution on the hair within 14 days of randomization. 5. Known history of irritation or sensitivity to pediculicides or hair care products. 6. Subjects with known allergy or hypersensitivity to Ivermectin or any component of the test product. 7. Any condition or illness that may compromise the objective of the protocol. 8. Subject receiving any other treatment which may interfere with the study results. 9. Participation in a previous investigational drug study within the past 30 days. 10. Does not understand the requirements for study participation and/or may likely exhibit poor compliance.

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of Ivermectin Lotion 0.5% w/w Versus Vehicle Control in lice infested subjects.Timepoint: at the end of 2 weeks

Secondary

MeasureTime frame
To evaluate the safety of Ivermectin Lotion 0.5% w/w Versus Vehicle Control in lice infested subjectsTimepoint: at the end of 2 weeks

Countries

India

Contacts

Public ContactDr Shailesh Singh

Ajanta Pharma Ltd

shailesh.singh@ajantapharma.com0226062111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026